Clinical Trial Update: A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for autologous tumor-infiltrating lymphocytes (TILs) in high-risk recurrent primary hepatocellular carcinoma (PHASE 1/PHASE 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Autologous tumor infiltrating lymphocytes (TILs)

Snippet

Sponsor: CAR-T (Shanghai) Cell Biotechnology Co., Ltd. | Conditions: Hepatic Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN